News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Pluri Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear Threat Concerns
Tuesday, November 26, 2024Pluri Inc a biotechnology company leveraging its proprietary platform for cellbased solutions to create a collaborative network of ventures today announced that it is assessing its readiness to initiate mass production of PLXR a novel potential treat...
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
Tuesday, November 26, 2024Eton Pharmaceuticals Inc an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases today announced that it has acquired the US rights to Amglidia glyburide oral suspension known as glibenclamide in Eu...
SCG Cell Therapy Presents Promising Phase 1 Data for a Novel HBV-Specific TCR-T Therapy (SCG101) at the AASLD Liver Meeting 2024
Monday, November 25, 2024SCG Cell Therapy Pte Ltd SCG a clinicalstage biotechnology company focused on developing innovative immunotherapies for infectious diseases and associated cancers announced latebreaking data from its Phase trial of SCG a firstinclass autologous hepa...
Acies Bio and Protein Evolution Announce Strategic Partnership to Advance Biological Recycling Technology
Friday, November 22, 2024Protein Evolution a pioneer in enzymedriven plastics recycling has announced a collaboration with Acies Bio an innovative biotechnology company specializing in microbial RD and biomanufacturing This partnership aims to leverage Acies Bios stateofthea...
Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
Friday, November 22, 2024Novartis announced an upgrade to its midterm guidance in advance of its Meet Novartis Management event for investors and analysts in London Previous guidance for sales CAGR was upgraded to driven by strong momentum of inmarket growth
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation
Thursday, November 21, 2024andMe Holding Co a leading human genetics and preventive health company and Mirador Therapeutics a nextgeneration precision medicine company focused on developing firstinclass or bestinclass therapeutics for immunology and inflammation IIrelated dise...
Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency
Thursday, November 21, 2024Capricor Therapeutics a biotechnology company developing transformative cell and exosomebased therapeutics for the treatment of rare diseases today announced that the European Medicines Agency EMA has granted both Orphan Drug and Advanced Therapy Med...
Steritas Announces Collaboration with argenx to Advance Evidence for Novel Steroid-sparing Therapeutics
Wednesday, November 20, 2024Steritas LLC a company dedicated to enhancing care for steroidtreated patients today announced a licensing agreement with argenx a global immunology company for use of its STOX Suite of steroidtoxicity clinical outcome assessments COAs across argenx
GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover
Wednesday, November 20, 2024GeneDx a leader in delivering improved health outcomes through genomic insights today announced GeneDx Discover a firstofitskind data visualization tool which provides biopharmaceutical companies access to deidentified and aggregated genetic data po...
Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy
Tuesday, November 19, 2024Trogenix Ltd today emerged from stealth mode to unveil its groundbreaking therapeutic platform for treating aggressive cancers Built from inception by BIO Capital which specialises in creating breakthrough therapeutic companies Trogenix spun out from...
